Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 173

Similar articles for PubMed (Select 22975805)

1.

The transcriptional landscape and mutational profile of lung adenocarcinoma.

Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, Lee J, Jung YJ, Kim JO, Shin JY, Yu SB, Kim J, Lee ER, Kang CH, Park IK, Rhee H, Lee SH, Kim JI, Kang JH, Kim YT.

Genome Res. 2012 Nov;22(11):2109-19. doi: 10.1101/gr.145144.112. Epub 2012 Sep 13.

2.

Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer.

Karlsson A, Brunnström H, Lindquist KE, Jirström K, Jönsson M, Rosengren F, Reuterswärd C, Cirenajwis H, Borg Å, Jönsson P, Planck M, Jönsson G, Staaf J.

Oncotarget. 2015 Jun 17. [Epub ahead of print]

3.

Profiling of oncogenic driver events in lung adenocarcinoma revealed MET mutation as independent prognostic factor.

Yeung SF, Tong JH, Law PP, Chung LY, Lung RW, Tong CY, Chow C, Chan AW, Wan IY, Mok TS, To KF.

J Thorac Oncol. 2015 Jun 19. [Epub ahead of print]

PMID:
26098749
4.

Genomic landscape of adenoid cystic carcinoma of the breast.

Martelotto LG, De Filippo MR, Ng CK, Natrajan R, Fuhrmann L, Cyrta J, Piscuoglio S, Wen HC, Lim RS, Shen R, Schultheis AM, Wen YH, Edelweiss M, Mariani O, Stenman G, Chan TA, Colombo PE, Norton L, Vincent-Salomon A, Reis-Filho JS, Weigelt B.

J Pathol. 2015 Jun 12. doi: 10.1002/path.4573. [Epub ahead of print]

PMID:
26095796
5.

RNA-seq analysis of lung adenocarcinomas reveals different gene expression profiles between smoking and nonsmoking patients.

Li Y, Xiao X, Ji X, Liu B, Amos CI.

Tumour Biol. 2015 Jun 17. [Epub ahead of print]

PMID:
26081616
6.

Identification and characterization of RET fusions in advanced colorectal cancer.

Le Rolle AF, Klempner SJ, Garrett CR, Seery T, Sanford EM, Balasubramanian S, Ross JS, Stephens PJ, Miller VA, Ali SM, Chiu VK.

Oncotarget. 2015 May 30. [Epub ahead of print]

7.

Co-occurring genomic alterations define major subsets of KRAS - mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.

Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Rodriguez-Canales J, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan YH, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV.

Cancer Discov. 2015 Jun 11. pii: CD-14-1236. [Epub ahead of print]

PMID:
26069186
8.

Next-generation sequencing for molecular diagnosis of lung adenocarcinoma specimens obtained by fine needle aspiration cytology.

Qiu T, Guo H, Zhao H, Wang L, Zhang Z.

Sci Rep. 2015 Jun 11;5:11317. doi: 10.1038/srep11317.

9.

Driver Gene Mutations in Primary Carcinoids of the Lung: Who Are the Best Candidates for Genetic "Next-Generation Sequencing"?

Lococo F, Ciarrocchi A.

Lung. 2015 May 26. [Epub ahead of print] No abstract available.

PMID:
26007156
10.

Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers.

Jang JS, Lee A, Li J, Liyanage H, Yang Y, Guo L, Asmann YW, Li PW, Erickson-Johnson M, Sakai Y, Sun Z, Jeon HS, Hwang H, Bungum AO, Edell ES, Simon VA, Kopp KJ, Eckloff B, Oliveira AM, Wieben E, Aubry MC, Yi E, Wigle D, Diasio RB, Yang P, Jen J.

Sci Rep. 2015 May 18;5:9755. doi: 10.1038/srep09755.

11.

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.

Paik PK, Drilon A, Fan PD, Yu H, Rekhtman N, Ginsberg MS, Borsu L, Schultz N, Berger MF, Rudin CM, Ladanyi M.

Cancer Discov. 2015 May 13. pii: CD-14-1467. [Epub ahead of print]

PMID:
25971939
12.

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill J, Lee C, Jentz D, Hoover R, Ou I, Salgia R, Brennan T, Chalmers Z, Jaeger S, Huang A, Elvin JA, Erlich R, Fichtenholtz A, Gowen KA, Greenbowe J, Johnson A, Khaira D, McMahon C, Sanford EM, Roels S, White J, Greshock J, Schlegel R, Lipson D, Yelensky R, Morosini D, Ross JS, Collisson E, Peters M, Stephens PJ, Miller V.

Cancer Discov. 2015 May 13. pii: CD-15-0285. [Epub ahead of print]

PMID:
25971938
13.

Lung cancer and metastasis: new opportunities and challenges.

Wang X, Adjei AA.

Cancer Metastasis Rev. 2015 May 9. [Epub ahead of print]

PMID:
25956388
14.

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.

Medico E, Russo M, Picco G, Cancelliere C, Valtorta E, Corti G, Buscarino M, Isella C, Lamba S, Martinoglio B, Veronese S, Siena S, Sartore-Bianchi A, Beccuti M, Mottolese M, Linnebacher M, Cordero F, Di Nicolantonio F, Bardelli A.

Nat Commun. 2015 Apr 30;6:7002. doi: 10.1038/ncomms8002.

PMID:
25926053
15.

Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment.

Suzuki A, Matsushima K, Makinoshima H, Sugano S, Kohno T, Tsuchihara K, Suzuki Y.

Genome Biol. 2015 Apr 3;16:66. doi: 10.1186/s13059-015-0636-y.

16.

Genomics driven-oncology: challenges and perspectives.

Normanno N, Cree IA.

BMC Cancer. 2015 Mar 23;15:141. doi: 10.1186/s12885-015-1147-7.

17.

Development of lung adenocarcinomas with exclusive dependence on oncogene fusions.

Saito M, Shimada Y, Shiraishi K, Sakamoto H, Tsuta K, Totsuka H, Chiku S, Ichikawa H, Kato M, Watanabe S, Yoshida T, Yokota J, Kohno T.

Cancer Res. 2015 Jun 1;75(11):2264-71. doi: 10.1158/0008-5472.CAN-14-3282. Epub 2015 Apr 8.

PMID:
25855381
18.

Whole exome sequencing identifies driver mutations in asymptomatic computed tomography-detected lung cancers with normal karyotype.

Belloni E, Veronesi G, Rotta L, Volorio S, Sardella D, Bernard L, Pece S, Di Fiore PP, Fumagalli C, Barberis M, Spaggiari L, Pelicci PG, Riva L.

Cancer Genet. 2015 Apr;208(4):152-5. doi: 10.1016/j.cancergen.2015.02.004. Epub 2015 Feb 20.

PMID:
25850996
19.

Protein domain-level landscape of cancer-type-specific somatic mutations.

Yang F, Petsalaki E, Rolland T, Hill DE, Vidal M, Roth FP.

PLoS Comput Biol. 2015 Mar 20;11(3):e1004147. doi: 10.1371/journal.pcbi.1004147. eCollection 2015 Mar.

20.

Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR.

Ha SY, Choi SJ, Cho JH, Choi HJ, Lee J, Jung K, Irwin D, Liu X, Lira ME, Mao M, Kim HK, Choi YS, Shim YM, Park WY, Choi YL, Kim J.

Oncotarget. 2015 Mar 10;6(7):5465-74.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk